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Abstract
Background: Measuring research impact is of critical interest to philanthropic and government funding agencies
interested in ensuring that the research they fund is both scientifically excellent and has meaningful impact into
health and other outcomes. The Beat Cancer Project (BCP) is a AUD $34 m cancer research funding scheme that
commenced in 2011. It was initiated by an Australian charity (Cancer Council SA), and supported by the South
Australian Government and the state’s major universities.
Methods: This study applied Buxton and Hanney’s Payback Framework to assess research impact generated from
the BCP after 3 years of funding. Data sources were an audit of peer-reviewed publications from January 2011 to
September 2014 from Web of Knowledge and a self-report survey of investigators awarded BCP research funding
during its first 3 years of implementation (2011–2013). Of the 104 surveys, 92 (88%) were completed.
Results: The BCP performed well across all five categories of the Payback Framework. In terms of knowledge
production, 1257 peer-reviewed publications were generated and the mean impact factor of publishing journals
increased annually. There were many benefits to future research with 21 respondents (23%) reporting career
advancement, and 110 higher degrees obtained or expected (including 84 PhDs). Overall, 52% of funded projects
generated tools for future research. The funded research attracted substantial further income yielding a very high
rate of leverage. For every AUD $1 that the cancer charity invested, the BCP gained an additional AUD $6.06. Five
projects (5%) had informed policy and 5 (5%) informed product development, with an additional 31 (34%) and 35
(38%) projects, respectively, anticipating doing so. In terms of health and sector and broader economic benefits, 8
(9%) projects had influenced practice or behaviour of health staff and 32 (34%) would reportedly to do so in the
future.
Conclusions: Research impact was a priority of charity and government funders and led to a deliberate funding
strategy. Emphasising research impact while maintaining rigorous, competitive processes can achieve the joint
objectives of excellence in research, yielding good research impact and a high rate of leverage for philanthropic
and public investment, as indicated by these early results.
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Background
Cancer death rates have continued to fall in Australia
since the 1980s, with incidence rates also decreasing.
During this time, survival rates have improved substan-
tially and some of these gains can be attributed to im-
provements in detection and developments in treatment
through research and new technologies [1]. According
to WHO, people living in Australia generally have better
cancer survival than those living in other countries and
regions [2]. However, there is much work yet to be done,
with more cancer cases being diagnosed each year in
Australia [1].
Translational research has been an important con-
tributor to reduced cancer incidence and increased sur-
vival. However, the process of translating research into
policy and practice is often convoluted and slow. It is
commonly stated that it takes an average of 17 years for
research evidence to be translated into clinical practice
[3–5]. With growing competition for the fundraising
dollar, charities are under increasing pressure to demon-
strate and report the impact of their work to the com-
munity, and governments are seeking to allocate scarce
resources effectively. As a result, researchers are increas-
ingly being asked to demonstrate the impact of their re-
search in terms of improved treatments and health gains
to inform funding decisions [6].
Measuring the impact of research is an important area,
and one that is relatively underdeveloped. In 2001, Smith
noted, “The main aim of health research is to improve
the health of people. Yet the performance of researchers
tends to be measured by the scientific quality of their re-
search rather than by its impact on health” [7].
Academic research metrics are focussed on peer-review
publications, journal quality and prestige, journal impact
factors, and article citations. While these measures are
important, particularly to measuring impact within the
scientific community, they do not measure impact in
terms of translation into practice and policy, or return
on investment and rate of leverage for charities and their
donors. The need to capture, measure and monitor re-
search impact more broadly is receiving increasing at-
tention in Australia and internationally [8–10].
Cancer Council SA is one of the largest cancer re-
search funding bodies in South Australia. Researchers go
through rigorous, competitive processes to obtain fund-
ing, which ensures that the research funded is of the
highest quality. Like many philanthropic agencies,
Cancer Council SA became increasingly interested in be-
ing able to capture and demonstrate to the community
the impact of the research that it was funding in terms
of cancer control. Within this context, they initiated a
review of the impact of the research they fund.
Cancer Council SA’s Beat Cancer Project (BCP) is an
AUD $34 m, 10-year competitive funding scheme for
cancer research in South Australia, funding over 100
cancer research initiatives in its first 3 years. Cancer
Council initiated the BCP with an AUD $10 m invest-
ment, matched by the South Australian Government (via
the Department for Health and Ageing) over 5 years.
Cancer Council then added a further AUD $7 m for the
next 5 years, which was matched by the South
Australian Government. BCP is underpinned by a stra-
tegic cancer research partnership with the South
Australian Health and Medical Research Institute and
the state’s three major universities (University of
Adelaide, Flinders University and the University of South
Australia). These universities provide additional matched
funding (along with other organisations) for the majority
of schemes within the competitively awarded research.
A widely accepted framework for evaluating the im-
pact of research is the Payback Framework [11–16], de-
veloped by Buxton and Hanney (Brunel University
London, United Kingdom) to examine the impact or
‘payback’ of health services research [17]. The Payback
Framework consists of two elements – a logic model of
the research processes and the five categories of ‘pay-
backs’ or impact that may be gained from research [17],
namely (1) knowledge production; (2) benefits to future
research and research use; (3) benefits to informing pol-
icy and product development; (4) health and sector ben-
efits; and (5) broader economic benefits. In Australia,
Donovan et al. [16] used the Framework to evaluate the
payback profiles of the National Breast Cancer Founda-
tion’s funded research over a 17-year period. The study
found that 46% of survey respondents reported career
progression, and 185 higher degrees were either ob-
tained or expected, including 121 PhDs. Overall, 66%
produced tools that built capacity across the research
system and research teams leveraged $1.40 in funding
for every $1 invested [16]. The Payback Framework has
been used in other fields of research, including cardio-
vascular research [6], arthritis research [11] and asthma
research [15]. However, the Payback Framework has not
yet been applied in a general cancer setting.
This study aims to assess the impact of a cancer re-
search funding programme, expanding beyond trad-
itional research metrics. This review applied the Payback
Framework to the BCP, which at the time of this review,
was in its third year. This is the first in-depth study of
the impact of a general cancer research programme
using the Payback Framework.
Methods
Records held by Cancer Council SA’s BCP
Administrative records were obtained for funded re-
search, including amounts of grant funding awarded.
BCP grants during 2011–2013 included infrastructure
grants to support clinical trials (ongoing); data linkage
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(ongoing); data collection systems and equipment (one-
off grants); research project grants (duration 1 year);
blue sky funding (1 year); partnership grants (3 years);
hospital research packages (up to 5 years) and workforce
funding, including research chairs/leaders (5 years); prin-
cipal research fellowships (4 years); fellowships (3 years);
PhD top-up scholarships (one-off grants); and travel
grants (one-off grants). The distribution of funding dur-
ing the study period (2011–2013) was 58.9% for biomed-
ical research, 21.6% for population/health services
research and 19.5% for clinical research and across the
cancer spectrum.
Publications audit
To assess knowledge production, a separate audit was
undertaken of all peer-reviewed papers published within
the period of January 1, 2011, and September 5, 2014, by
chief investigators using Web of Knowledge. The audit
was undertaken separately to the survey of chief investi-
gators to reduce respondent burden and to reduce the
potential negative impact on response rates. The jour-
nals published in most frequently were tabulated to con-
struct a list of the top 20.
Survey of chief investigators
A survey tool was developed using the key concepts
from the Payback Framework and its five categories of
impact. The survey was also consistent with the National
Breast Cancer Foundation (NBCF) survey (14). A full list
of questions is included in Additional file 1.
The survey was emailed to 104 BCP recipients in June
2014 (six recipients had multiple funding on similar pro-
jects so they were asked to complete one survey only).
The response rate for the surveys was 88% (92/104).
Data were analysed using SPSS version 22.
Results
Knowledge production
Publications
In total, 1257 peer-reviewed publications were generated
by BCP recipients over the 3-year period, yielding an aver-
age of 11.3 per grant awarded. The impact factor for the
journals in which BCP researchers published most fre-
quently increased annually, from 3.84 in 2011 to 6.74 in
2013, indicating that, over time, work is being published
in higher impact journals. The overall impact factor for
the journals in which BCP recipients most commonly
published in over the period was 6.40. Table 1 presents
the 20 peer-reviewed journals most commonly published
in for the study duration. Table 2 outlines the most com-
monly cited article for the three funding categories (bio-
medical, clinical and population health/services).
Dissemination
BCP recipients disseminated knowledge produced out-
side of peer-reviewed publications. Aside from publica-
tion, the most popular methods of dissemination were
oral presentations, posters, conferences and workshops
for academics (n = 590), overall representing 6.4 presen-
tations/posters per survey grant respondent. This was
followed by general public presentations (n = 75; 0.82
per grant), newspaper articles (n = 36; 0.39 per grant),
radio interviews (n = 29; 0.32 per grant) and television
interviews (n = 19; 0.21) per grant.
Benefits to future research and research use
Research training and career development
Funded researchers reported that 110 higher degrees (1.2
per grant) were awarded or expected in the next 5 years,
including 84 PhDs as a direct consequence of BCP fund-
ing. In addition, 21 (22.8%) reported that participation in
the research led to career advancement for members of
the funded research team (e.g. an advancement from
Senior Lecturer to Professor).
Table 1 Top 20 peer-reviewed journals most commonly pub-
lished in for 2011–2013
Journal Number of
publications
Impact factor
(Web of Knowledge 2012)
Blood 60 9.78
Journal of Clinical Oncology 48 18.04
Asia Pacific Journal
of Clinical Oncology
47 0.91
PLoS One 18 3.73
Leukemia 17 10.16
Medical Journal of Australia 15 2.85
Supportive Cancer Care 14 3.09
Gastroenterology 12 12.82
Journal of Gastroenterology
and Hepatology
12 3.33
Cell Death and Differentiation 11 8.24
Oncogene 11 7.36
ANZ Journal of Surgery 10 1.50
International Journal of Cancer 10 6.20
Oncotarget 10 6.64
Haematologica 9 5.94
Cancer Biology and Therapy 9 3.29
British Journal of Haematology 8 4.94
Journal of Clinical Investigation 8 12.81
British Journal of Cancer 8 5.08
Asian Pacific Journal
of Cancer Prevention
8 1.27
Average Total N/A 6.40
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Capacity-building
BCP recipients reported that 48 funded projects (52.2%)
had generated tools (including improved websites, ques-
tionnaires and registries to procedures, methods and
markers for early detection) for future research as a re-
sult of the funded research that would help to build cap-
acity across the research system.
Attracting further income and generating further research
Further income
The BCP’s investment of AUD $10.4 m during the study
period yielded further funding to the amount of AUD
$26.3 m (AUD $12.5 m in matched funding from univer-
sities and an additional AUD $13.8 m in further research
funding from other sources, e.g. NHMRC). Thus, for
every AUD $1 invested by the BCP ($0.50 by SA Health
and $0.50 by Cancer Council SA), research teams gained
an additional $2.53. Or in other funding leverage terms,
for the AUD $5.2 m invested by Cancer Council SA, a
further AUD $31.5 m was achieved in funding from
other sources (SA Health, Universities, NHMRC, etc.),
meaning that, for every Australian dollar invested by
Cancer Council SA on behalf of their donors, the BCP
gained an additional AUD $6.06.
Further research
Overall, 38 (41.3%) of BCP investigators reported that
their funded research findings, methodology or theoret-
ical developments generated subsequent research. In
addition, 16 investigators reported that their research
contributed to research conducted by others.
Benefits from informing policy and product development
Policy development
Impact into policy and practice had already occurred in
some instances, despite the short 3-year time frame,
but was most frequently intended for the future. The
survey found that five BCP recipients reported that
their results had been used in policy and decision-
making and a further 31 (34%) reported that they plan
to do so in the future, but that the timeframe since
BCP funding has been insufficient to have done so yet.
Actual use ranged from impact on refined treatment
guidelines for colorectal cancer, high-risk patients, liver
transplant and liver resection patients, the management
of women with early breast cancer (including stratifica-
tion of women according to their risk of subsequent
breast cancer), physical activity for cancer survivors, to
promoting case conferencing for palliative care, in-
creasing expenditure on anti-smoking mass media, and
Table 2 Most commonly cited article for the three funding categories
Research category Paper Citations (Google
scholar 2013)
Clinical Falchook G, Long G, Kurzrock R, Kim K, Arkenau T, Brown M, et al. Dabrafenib in patients with
melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Lancet. 2012;379(9829):1893–901.
136
Biomedical Chau N, Mackenzie P, Miners J. The contribution of human udp-glucuronosyltransferase enzymes to the
glucosidation of mycophenolic acid. Drug Metab Rev. 2014;45:S1.
129
Population/health services Hutchinson A, Wilson C. Improving nutrition and physical activity in the workplace: a meta-analysis of
intervention studies. Health Promot Int. 2012;27:2.
14
Fig. 1 Intended and actual use in informing policy development/decision-making by main research type (frequency)
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informing position statements for the non-government
sector. Expected use ranged from use in state and na-
tional policy in tobacco control and obesity, to guid-
ance on improvements for the health of Aboriginal and
Torres Strait Islander communities, and clinical man-
agement of women with screen-detected breast lesions.
Population health/health services researchers listed 35
ways of expected/actual use, whereas biomedical re-
searchers listed 20 and clinical researchers listed 19.
There were differences in the levels at which policies
were, or were likely to be, influenced by research type
(Fig. 1). The impact (or intended impact) of population
and health services research was most often in govern-
ment policies and hospital/local practice and policy.
Biomedical research was reported as being most likely
to impact clinical guidelines and healthcare bodies in
other countries. Clinical research was reported to be
most likely to impact clinical guidelines, and curricu-
lum or training.
In total, 58% of projects reported that they had inter-
action with end-users of their research, namely policy-
makers, practitioners and/or consumers, either before
(39.1%), during (43.5%) or after project completion
(34.8%). Further analysis revealed that a higher propor-
tion of population/health services (71%) and clinical
researchers (67%) had engagement than biomedical re-
searchers (54%).
Product development
Five (5%) BCP recipients reported that they had used
their results to inform product development (including
pharmaceuticals, diagnostic tests, medical devices, etc.)
and a further 35 (38%) expected their research to do so
in the future.
Health gains and broader economic benefits
Survey results found that 8 (9%) BCP recipients reported
influencing practice or behaviour of health service staff,
patients and the public, and a further 32 (35%) reported
that their projects would do so in the future. Actual and
expected benefits ranged from decreasing the side-
effects of cancer treatments to prevention and early de-
tection. The majority of participants reported that they
had increased, or expected to do so, the length or quality
of life for people with cancer (57%). There were differ-
ences in the levels at which policies were, or were likely
to be, influenced by research type (Fig. 2).
Discussion
With more cancer cases being diagnosed each year in
Australia, there is a responsibility to ensure that the re-
search conducted is of high impact. This study is the
first of its kind attempting to capture research impact in
a general cancer research setting. The NBCF study used
a similar methodology for their research investment, and
therefore some basic comparisons can be made. How-
ever, it is important to note that Cancer Council SA’s
BCP had only been funded for 3 years at the time of the
survey, compared with the NBCF study that evaluated
funding over a 17-year period. The high response rate
for this survey means that the conclusions are represen-
tative of the whole BCP portfolio.
The BCP had outstanding performance in generating
further research and funding, an important outcome for
the funders and donors. Due to its unique and deliberate
funding strategy, the BCP demonstrated a very high rate
of leverage for Cancer Council SA donors, whereby, for
every AUD $1 donated, the BCP gained an additional
AUD $6.06 in research funding. In terms of return on in-
vestment, for every AUD $1 spent by the BCP, research
Fig. 2 Actual and intended impacts to practice and behaviour (frequency)
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teams gained an additional AUD $2.53. This compares
very favourably to the NBCF investment (which had a dif-
ferent strategy and may not have required universities to
co-invest) where, for every AUD $1 spent, an additional
AUD $1.40 was leveraged [16]. This result highlights the
potential of charities working with governments and other
funding bodies to achieve a high return on investment
and rate of leverage for donors.
The BCP had slightly less impact than the NBCF in terms
of knowledge production. Research dissemination in the
form of conference presentations appeared to be slightly
lower for BCP recipients (6.4 per grant) compared to the
NBCF-funded research (8.0 per grant). Interviews with the
media were also lower in BCP participants (0.45 per grant)
compared to NBCF grant recipients (1.1 articles per grant).
These results most likely reflect the longevity of the NBCF
funding programme and the experience its funded re-
searchers have with NBCF’s expectations in this regard.
Overall, the two Australian cancer research funding
programmes were comparable in engagement with
end-users, consumers, clinicians and policy-makers
(58% in BCP and 56% in NBCF), as well as in re-
search training, with BCP resulting in 110 higher de-
grees obtained or expected (1.2 per grant) compared
with 185 by NBCF (1.2 per grant). Career develop-
ment took place in 23% of BCP team members (over
a 3-year period) compared with 50% in the NBCF
(over a 17-year period).
Importantly, this study found that, by purposefully
funding research across the spectrum (biomedical, clin-
ical and population/health services research), there was
diversity in the impact on policy, practice and behaviour,
health gain and broader economic impacts. For example,
population health research was more likely to impact on
government health policy, whereas clinical practice,
training and curriculum were more likely to be impacted
by clinical research, which is likely to yield greater out-
comes for the community and people affected by cancer.
The results of this study have been incorporated into a
review of the scheme and its renewal for a further
5 years. The results provide further substantiation to the
funders’ strategy of funding across all three streams, and
have led to a marginal adjustment of funding ratios.
Impact evaluation will also be embedded in future sur-
veys and another in-depth study will be undertaken in
5 years with these recipients to determine whether the
intended impacts have indeed come to fruition.
Limitations
It is important to note that caution must be applied when
interpreting the results as there has been a very short-time
frame between the commencement of this project and the
survey. The often cited time-lag in translation of research
is 17 years [5]; thus, with this in mind, the findings of this
study should be viewed as early impact. In addition, the
audit of peer-reviewed publications is merely indicative
and further bibliometric analysis by funding type would be
beneficial as would analysis by alternative traditional
metrics such as citations (or other measures) rather than
relying on impact factors. Impact factors are now widely
criticised as a flawed indicator for the quality of each indi-
vidual paper within that journal [18]. Furthermore, the
methods of actual translation and impact factors for popu-
lation health and health services journals are often quite
different to the impact factors for clinical and biomedical
journals and are therefore not directly comparable.
Responses within the survey are largely self-reported, with
the inherent biases that self-reporting brings. In addition,
in order to increase response rates, chief investigators
were asked to complete the report as a condition of fund-
ing and were advised that a failure to submit the report
may render them ineligible for future funding. This is
likely to have increased response rates but may also
impact on responder bias. While reports of actual impact
can be verified, projections of future impact are much
harder to check for likelihood. The BCP has been funded
for a second 5-year term and a further impact assessment
is recommended, allowing more accurate assessment of
actual impact as well as a comparison of projected and
actual impact.
Conclusion
This is the first study of its kind using the Payback
Framework in a general cancer research setting. Despite
the short time frame, results are favourable and highlight
the potential importance of setting impact evaluation in
place at the commencement of funding to influence ex-
penditure around research impact. The BCP compared
well with a previous study on all categories and compared
particularly well in generating further funds to build upon
the research (for every $1 spent by the BCP, a further $2.
53 were generated by research teams). This survey high-
lights the potential importance of funding research in all
areas (biomedical, clinical and population health/health
services research) to achieve and maximise payback on all
of the categories. This may serve to maximise impact of
research, which is likely to translate to broader impacts
for the community. Ultimately, with translational research
being funded across the spectrum, there is a likelihood
that more cancers will be prevented, rates for people with
cancer may be increased, and the journey for those
affected by cancer is likely to be improved. This study can
provide a benchmark for other research in the general
cancer setting and for future assessments of the BCP. The
results of this study are timely in the context of increasing
pressure by governments and charities to justify the im-
pact of their funded research more broadly.
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